Another study using dimerized amidobenzimidazole (diABZI) reagents to activate STING controlled CT-26 tumor growth and promoted survival when administered intravenously, although diABZI treatment was initiated just 2 days after CT-26 engraftment.37 Thus, STING activators may have considerable potential as antitumor immune adjuvants but use of clinically unfeasible treatments and outcome measures lacking rigor make it difficult to estimate the likely efficacy of STING activators in patients. The gene discussed is STING1; the disease is neoplasm.